According to a recent study, GLP-1 receptor agonists may have potential applications as adjunct therapy for psoriasis, atopic dermatitis, hidradenitis suppurativa, chronic wounds, and other skin conditions.
Children, elderly cases of viral skin diseases rising
According to a recent study, rates of viral skin diseases have been rising globally, with the highest increases among children and the elderly.
Exercise, diet, psychological interventions may complement conventional therapy for PsO
According to a recent study, lifestyle changes and nutritional interventions may complement conventional therapy for psoriasis patients.
Novel retinoid, salicylic acid topical effective in treating acne, PIH
According to a recent study, combination therapy with site-specific salicylic acid and retinol demonstrated significant clinical improvement in acne and post-inflammatory hyperpigmentation (PIH).
PsO patients trust topicals less than AD patients
According to a recent study, trust levels regarding topical therapy were higher among atopic dermatitis (AD) patients than psoriasis (PsO) patients.
Text message intervention effective in improving cardiovascular risk in PsO patients
According to a recent study, a text message intervention system improved cardiovascular risk behaviours and patient confidence managing their health in adult psoriasis patients.
AD associated with increased risk of retinal detachment
According to a recent study, patients with atopic dermatitis (AD) have an increased risk of retinal detachment and postoperative proliferative vitreoretinopathy (PVR).
Researchers develop intelligent tattoo to detect melanoma
Researchers have developed a minimally invasive ‘intelligent tattoo’ for the early detection of melanoma or micro-melanoma.
Concomitant ixekizumab, tirzepatide improves skin clearance, reduces weight in PsO patients
According to a recent study, concomitant ixekizumab and tirzepatide improved skin clearance and reductions in weight in patients with moderate-to-severe psoriasis.
Risankizumab linked to lower risk of serious infection than other systemic treatments
According to a recent study, risankizumab was associated with a lower risk of serious infections when compared to other systemic treatments for psoriasis.
